Extension of Advanced Biopharmaceutical Supply Contract Secures Stable Revenue Base Through 2027
Correction disclosure extends contract period by one year to August 31, 2027, from the previous end date of July 31, 2026
Contract amount remains at KRW 1,917,493,000 (approx. 19.17 billion won), representing 26.6% of 2024 sales of KRW 7,209,317,184 (approx. 72.09 billion won)
Contract involves manufacturing and supply of advanced biopharmaceuticals; in-house production, not conditional
Simple extension with no additional fundraising or equity dilution, leaving existing shareholder value unaffected
Disclosure delayed due to counterparty's confidentiality request, but this is standard and not an additional risk
[AI Summary]The contract extension enhances stability of a key revenue stream (26.6% of sales), positive signal; investment risk is low, favorable for medium- to long-term stock outlook
KOSDAQ Filing Information
Filing: [Correction of Description] Conclusion of Single Sale and Supply Contract